阿尼制药 ANIP 深 沪
已收盘 05-22 16:00:00 美东时间
82.72
-0.050
-0.06%
华盛通- 最 高83.52
- 今 开82.80
- 成交量 56.24万股
- 最 低 81.28
- 昨 收 82.77
- 总市值 18.82亿
- 52周最高 99.50
- 市盈率 静 24.88
- 换手率 2.47%
- 52周最低 58.70
- 委 比 -49.82%
- 总股本 2274.55万
- 历史最高 99.50
- 量 比 1.98
- 振 幅 2.71%
- 历史最低 0.80
- 每 手 1
- 风险率 10.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ANI Pharmaceuticals Shareholders Approve Amended 2022 Incentive Plan
ANI Pharmaceuticals ( ($ANIP) ) just unveiled an update. ANI Pharmaceuticals, I...
05-22 04:31
财报速睇 | 阿尼制药 2026财年Q1营收2.37亿美元，同比增长20.5%；归母净利润0.12亿美元，同比增长390.7%
华盛资讯5月13日讯，阿尼制药公布2026财年Q1业绩，公司Q1营收2.37亿美元，同比增长20.5%，归母净利润0.12亿美元，同比增长390.7%。
05-13 20:47
ANI Pharmaceuticals Updates Investor Presentation, Highlights Non-GAAP Metrics
ANI Pharmaceuticals ( ($ANIP) ) has provided an update. On May 13, 2026, ANI Ph...
05-13 20:44
U.S. RESEARCH ROUNDUP-Airbnb, HII, Tesla
U.S. RESEARCH ROUNDUP-Airbnb, HII, Tesla May 11 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Airbnb, HII and Tesla on Monday. HIGHLIGHTS * Airbnb Inc ABNB.O : Jefferies raises target price to $175 from $165 - * ANI Ph
05-11 15:27
ANI Pharmaceuticals Q1 revenue rises 21%, adjusted EPS beats estimates
ANI Pharmaceuticals Q1 revenue rises 21%, adjusted EPS beats estimates Overview US biopharma firm's Q1 revenue rose 20.5%, beating analyst expectations Adjusted EPS for Q1 beat analyst expectations Company authorized $100 mln share repurchase program Outlook ANI Pharmaceuticals raises 2026 total net
05-08 18:59
ANI Pharmaceuticals Raises FY2026 Adj EPS Guidance from $8.83-$9.34 to $9.19-$9.69 vs $9.07 Est; Raises FY2026 Sales Guidance from $1.055B-$1.115B to $1.080B-$1.140B vs $1.050B Est.
ANI Pharmaceuticals (NASDAQ:ANIP) raises FY2026 Adj EPS guidance from $8.83-$9.34 to $9.19-$9.69 vs $9.07 analyst estimate. Raises FY2026 sales outlook from $1.055 billion-$1.115 billion to $1.080 billion-$1.140 billion
05-08 18:52
ANI Pharma Q1 FY26 net income rises 93.1% to USD 29.5 million; revenue increases 20.5% to USD 237.5 million
ANI Pharma Q1 FY26 net income rises 93.1% to USD 29.5 million; revenue increases 20.5% to USD 237.5 million ANI Pharmaceuticals Q1 net revenues rose 20.5% to USD 237.5 million. Net income available to common shareholders climbed to USD 29.5 million; diluted GAAP EPS increased to USD 1.28. Adjusted n
05-08 18:51
ANI Pharmaceuticals Q1 Adj. EPS $2.05 Beats $1.30 Estimate, Sales $237.462M Beat $207.565M Estimate.
ANI Pharmaceuticals (NASDAQ:ANIP) reported quarterly earnings of $2.05 per share which beat the analyst consensus estimate of $1.30 by 56.49 percent. This is a 20.59 percent increase over earnings of $1.70 per share from
05-08 18:50
ANI Pharmaceuticals schedules webcast to discuss first-quarter results
ANI Pharmaceuticals schedules webcast to discuss first-quarter results ANI Pharmaceuticals will release first-quarter 2026 financial results on May 8, 2026, before market open. Management will host webcast and conference call at 8:00 a.m. ET on May 8, 2026. Webcast access will be posted on anipharma
04-24 18:50
ANI Pharmaceuticals Announces Launch Of Pimozide Tablets 1 Mg And 2 Mg, Generic Version Of Reference Listed Drug Orap
ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI's Pimozide Tablets is the generic version of the reference listed drug (RLD) Orap®."We
04-20 18:51
